Summary
What does MFN mean for pricing strategies, market access, and the future of global healthcare systems? Daniel Suhr, CEO of Two Scenarios, explores the implications of Most Favoured Nation policies and the questions life science companies should be asking now.
Speaker
Daniel Suhr is CEO of Two Scenarios and a pharmaceutical pricing expert with extensive experience in global pricing strategies and international reference pricing. He helps life science companies navigate complex pricing and market access challenges and optimise their approach to global pharmaceutical markets.
Atrium Pulse
Is our webinar series made to inspire and connect life science professionals with the experts shaping the industry’s future.
Every two weeks, we pair 15 minutes of sharp insight from a leading voice in the field with 15 minutes of live Q&A - free, online, and open to everyone curious about where life science is heading.
Key words
- Market Access
- Pharmaceutical Pricing
- International Reference Pricing
- Most Favoured Nation (MFN)
- Global Pricing Strategy
Save information for later
Course leader & lecturers
- Daniel SuhrLecturerCEO
Two Scenarios
Watch the video
Is this course for you?
If you work in life science and are curious about the trends, innovations, and perspectives shaping the future of the industry, this webinar is for you.
What you will learn
- Gain insights into how MFN policies and international reference pricing can influence pharmaceutical pricing and market access strategies.
What your company will get
- An employee with a broader understanding of the global pricing dynamics shaping the pharmaceutical industry.
Course calendar
Day 1
- A 15 minute expert presentation followed by a 15 minute live Q&A
Course information
Literature
Prerequisites
None
Examination
Course leader
Lecturer
Two Scenarios
30 Sep 2026
•
•